Fung M, et al. - In this Surveillance, Epidemiology, and End Results (SEER)–Medicare cohort study, infectious complications linked with bendamustine-containing regimens among older patients with indolent non-Hodgkin lymphoma (iNHL) were investigated. Among 9,395 patients with iNHL (follicular, marginal zone, Waldenström macroglobulinemia) treated with chemotherapy from 2006 to 2013, 13% received regimens that contained bendamustine. Researchers observed an increased risk of both common infections (such as bacterial pneumonia) and opportunistic infections (such as cytomegalovirus, varicella zoster virus, histoplasmosis, and Pneumocystis jirovecii pneumonia) in association with bendamustine treatment. Patients receiving bendamustine as part of later (third-line and above) regimens displayed a higher risk for infections, which was independently associated with well-established issues such as neutropenia and corticosteroid exposure.